Buprenorphine/naloxone sublingual film

Drug Profile

Buprenorphine/naloxone sublingual film

Alternative Names: Naloxone/buprenorphine; SCH 000484; Suboxone; Suboxone film

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Reckitt Benckiser Pharmaceuticals
  • Developer Indivior; MonoSol Rx; Reckitt Benckiser Pharmaceuticals
  • Class Antidotes; Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Opioid abuse

Most Recent Events

  • 01 Mar 2016 Reckitt Benckiser Pharmaceuticals completes a phase I trial in Opioid abuse in USA (NCT02559973)
  • 01 Sep 2015 Reckitt Benckiser Pharmaceuticals initiates enrolment in a phase I trial for Opioid abuse in USA (NCT02559973)
  • 25 Feb 2013 First generic equivalent approved in USA for Opioid abuse
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top